Product tanker owners are again facing a threat from larger crude carriers cleaning up to load refined cargoes. The latest ...

Even the CEOs of Big Pharmas have come under fire. Activist investor Starboard Value has made no secret of its criticism of Pfizer CEO Albert Bourla’s track record, while GSK CEO Emma Walmsley fought ...

(Reuters) -Current weight-loss methods such as lifestyle changes, surgery, and popular therapies like Novo Nordisk's Wegovy and Eli Lilly's Zepbound result in both fat and muscle loss that can ...

View the latest Keros Therapeutics Inc. (KROS) stock price, news, historical charts, analyst ratings and financial information from WSJ.

Fintel reports that on June 10, 2025, B of A Securities downgraded their outlook for Keros Therapeutics (NasdaqGM:KROS) from Buy to Neutral. Analyst Price Forecast Suggests 89.41% Upside As of ...

On Tuesday, BofA Securities adjusted its stance on Keros Therapeutics (NASDAQ: KROS), downgrading the stock from Buy to Neutral and reducing the price target from $32.00 to $18.00. The decision ...

Analyst cuts Keros rating to Neutral, citing limited near-term catalysts and cautious investor sentiment. $375M capital return announced, but unclear structure and delayed KER-065 updates weigh on ...

Bank of America Securities analyst Jason Zemansky downgraded Keros Therapeutics, Inc. (NASDAQ:KROS) from Buy to Neutral, lowering the price forecast from $32 to $18. Zemansky noted that Keros has ...